May 10, 2017 9:19pm
I kept saying the cell therapy sector was stalled due to being oversold
Pre-open indications: 5 hits and 0 miss,
Investors are not as complacent as they have seemed as “our” universe’s companies needs to execute and communicate - utilizing those who “spread the message”!
There are many companies that I believe can do “it” better – JOIN me to get the “story” out and accepted!
I tick some CEOs off. As the leading voice of cell therapy “investors”; I am not always a doom and gloom reporter but a man who has been “there” with the gray hair and a readership following with real numbers to prove it!
I answer one question, in which company should investors commit and keep their money
RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.
Investors are not as complacent as they have seemed as “our” universe’s companies needs to execute and communicate - utilizing those who “spread the message”!
There are many companies that I believe can do “it” better – reiterating ... JOIN me!
Henry’omics:
From the pre-open’s investor’s newsletter “it’s time for a bounce … As I had stated, I believe, post reporting - some share pricing bounces are anticipated.”
- Reiterating, “Traders should be gearing up for the oversold … While the invested are at the same time optimistic and wary about share pricing.”
On Tuesday, Trump terminated James Comey's role at the FBI … as I had stated this firing issue would have some concerns in the market and … it <would>impede any confidence in today’s sessions.
Many years ago, I served in the FBI for five (5) years and saw the politicization and its effect and it scares me now!
- What I saw today, the reaction to Comey's firing in the market was largely muted because a large number of investors still believe the market will get tax reform at some point. But others were worried that Comey's abrupt dismissal could delay key items in the administration's agenda, including corporate tax reform and deregulation. <CNBC>
Don’t make the mistake of reacting to each and every news story as it hits the wires.
- The sector and markets always anticipate … whether a brief pop or with traders selling into strength!
What will happen in the short-term?
- We need to anticipate and move before event. That’s why it pays for investors to read the sector’s mood and ignore pay attention to the metrics of interest – volume, volatility and relative strength – basically the fundaments.
Anticipation and expectation will be MY new tools to utilize in measuring the future.
On Wednesday, the pain versus the gain decreased as financial results stepped further in getting completed and the sector bounced back … as seen in the increases in the advance/decline lines and a positive close after six down sessions.
Sorry, I didn’t hit all the bases with today’s quarterlies – I will catch up – a day of medical tests slows one down!
.... Paying for a past life ...
As quarterly results complete the course, we’ll be back to the norm of the roller-coaster
News, better guidance and reporting will cause the sector to run albeit slowly up
Daily analytics:
U.S. equities closed MIXED on Wednesday … with the DOW closing down -0.16% (-32, 67) as the NASDAQ also closed up +0.14% (+8.56) …
The cell therapy sector had more than a number of upside moves after reporting Q1/17 results as investors celebrated the bereavement of the oversold.
… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10 ….
· Tuesday traded below 10, not seen since December 2006 while Monday traded near 10 after Friday’s near 10.7 following Thursday’s 10.48 and last Wednesday ‘s near 10.7;
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated a negative -0.34% at the pre-open was and closed UP +0.62% following Tuesday’s -0.03% versus Monday’s -0.24%;
… The iShares NASDAQ Biotechnology (IBB) indicated a negative -0.12% at the pre-open and closed DOWN -0.34% following Tuesday’s +1.21% versus Monday’s -2.17%
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The open was negative with an A/DL of 17/20 and 6 flats –;
· The mid-day flipped positive with an A/DL of 24/15 and 4 flats;
· The close was positive with an A/DL of 27/14 and 4 flats;
The count - decliners versus gainers: look at the differences in the spreads and advance/decline lines:
· Wednesday’s decliners ranged from -0.48% <VTGN> to -7.92% <RGNX> in 14 equities;
· Tuesday’s decliners ranged from -0.07% <MDXG> to -27.70% <CUR> in 22 equities;
· Monday’s decliners ranged from -0.65% <CAPR> to -13.56% <CUR> in 28 equities;
Versus
· Wednesday’s gainers ranged from +0.03% <OPXA> to +36.18% <CUR> in 27 equities;
· Tuesday’s gainers ranged from +0.04% <CLLS> to +6.41% <JUNO> in 18 equities;
· Monday’s gainers ranged from +0.37% <ONVO> to +11.84% <OSIR> in 12 equities;
Pre-open indications: 5 hit and 1 miss
- Athersys (ATHX) closed up +$0.05 – hit;
- bluebird bio (BLUE) closed up +$1.15 – hit;
- Cellectis SA (CLLS) closed up +$0.27 – hit;
- Kite Pharma (KITE) closed up +$2.88 – hit;
- Regenxbio (RGNX) closed down -$1.50 – hit;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
